
IDEXX Laboratories (IDXX) Stock Forecast & Price Target
IDEXX Laboratories (IDXX) Analyst Ratings
Bulls say
IDEXX Laboratories demonstrates strong customer retention rates of approximately 97%, enhancing the predictability of its revenue and earnings streams. The company has achieved a notable compound annual growth rate (CAGR) of around 16% in organic consumables revenue from 2016 to 2022, reflecting durable growth in its recurring revenue segment. Moreover, IDXX's total suite of offerings has resulted in customers exhibiting 3.5 times higher growth across all testing categories, positioning the company favorably for continued expansion in the pet care market.
Bears say
IDEXX Laboratories has experienced a decline in clinical vet visits, with a year-over-year decrease of -1.7% in Q4 2025, signaling a concerning trend compared to previous quarters. This downturn is further compounded by a projected decline of 200 basis points in end market pet visits for 2026, predominantly attributed to constraints faced by lower income pet owners. Additionally, economic challenges could impact both customers and suppliers, potentially leading to reduced demand for IDEXX's products and hampered financial performance.
This aggregate rating is based on analysts' research of IDEXX Laboratories and is not a guaranteed prediction by Public.com or investment advice.
IDEXX Laboratories (IDXX) Analyst Forecast & Price Prediction
Start investing in IDEXX Laboratories (IDXX)
Order type
Buy in
Order amount
Est. shares
0 shares